Nasdaq:US$19.70 (-0.20) | HKEX:HK$31.35 (-0.05) | AIM:£3.13 (-0.02)
Dr. Renu Bhatia

Dr Renu Bhatia has been an Independent Non-executive Director of the Company since 2024. She is also a member of the Technical Committee of the Company. A licensed physician, she has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors.

 

Dr Bhatia is the chairman and co-founder of Opharmic Technology (HK) Ltd, a company focusing on the development of ultrasound technology for non-invasive drug delivery to the eyes. She is also co-founder of Asia Fintech Angels which invested in early stage fintech companies. In addition, Dr Bhatia is an independent non-executive director of Overstone Associates Limited, a leading UK based data science provider to financial institutions focused on the art industry. Dr Bhatia is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited.  She also holds positions in public service including membership of the Business Professional Federation Healthcare Committee and the Cyberport Entrepreneurship Centre Advisory Group, and acting as an assessor for the Hong Kong Enterprise Support Scheme Assessment Panel of the Innovation and Technology Fund. Dr Bhatia started her career in finance at Goldman Sachs and HSBC Asset Management.

 

Dr Bhatia is a Doctor of Medicine (MBBS) from the University of London and holds a Master of Business Administration degree from Yale University, and a Postgraduate Diploma in Therapeutics and Medicine from The University of Hong Kong.